U.S. markets closed
  • S&P Futures

    3,884.00
    -14.75 (-0.38%)
     
  • Dow Futures

    31,392.00
    -117.00 (-0.37%)
     
  • Nasdaq Futures

    13,239.75
    -40.00 (-0.30%)
     
  • Russell 2000 Futures

    2,259.10
    -15.70 (-0.69%)
     
  • Crude Oil

    59.57
    -1.07 (-1.76%)
     
  • Gold

    1,709.00
    -14.00 (-0.81%)
     
  • Silver

    26.12
    -0.55 (-2.07%)
     
  • EUR/USD

    1.2025
    -0.0035 (-0.29%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3889
    -0.0032 (-0.23%)
     
  • USD/JPY

    106.7510
    +0.0210 (+0.02%)
     
  • BTC-USD

    49,191.57
    +2,826.79 (+6.10%)
     
  • CMC Crypto 200

    987.67
    +59.44 (+6.40%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,554.75
    -108.75 (-0.37%)
     

At US$309, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Today we're going to take a look at the well-established Bio-Techne Corporation (NASDAQ:TECH). The company's stock received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, what if the stock is still a bargain? Let’s examine Bio-Techne’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

Check out our latest analysis for Bio-Techne

Is Bio-Techne still cheap?

The share price seems sensible at the moment according to my price multiple model, where I compare the company's price-to-earnings ratio to the industry average. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 47.72x is currently trading slightly above its industry peers’ ratio of 43.88x, which means if you buy Bio-Techne today, you’d be paying a relatively sensible price for it. And if you believe that Bio-Techne should be trading at this level in the long run, then there should only be a fairly immaterial downside vs other industry peers. So, is there another chance to buy low in the future? Given that Bio-Techne’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility.

Can we expect growth from Bio-Techne?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Though in the case of Bio-Techne, it is expected to deliver a negative earnings growth of -11%, which doesn’t help build up its investment thesis. It appears that risk of future uncertainty is high, at least in the near term.

What this means for you:

Are you a shareholder? Currently, TECH appears to be trading around industry price multiples, but given the uncertainty from negative returns in the future, this could be the right time to reduce the risk in your portfolio. Is your current exposure to the stock optimal for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on TECH, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on TECH for a while, now may not be the most advantageous time to buy, given it is trading around industry price multiples. This means there’s less benefit from mispricing. In addition to this, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven’t considered today, which can help crystallize your views on TECH should the price fluctuate below the industry PE ratio.

So while earnings quality is important, it's equally important to consider the risks facing Bio-Techne at this point in time. At Simply Wall St, we found 1 warning sign for Bio-Techne and we think they deserve your attention.

If you are no longer interested in Bio-Techne, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.